Cure My Disease

Don't miss your cure!

 Log in / Sign up

New leukemia drug tested in japanese patients – early results promising?

NCT ID NCT06649006

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Nov 20, 2025 · Last updated May 15, 2026 · Updated 23 times

Summary

This early-stage study tested the safety of blinatumomab in 6 Japanese adults newly diagnosed with a type of leukemia (B-ALL). The main goal was to see what side effects occurred. Participants received the drug through an IV after initial chemotherapy. Results help guide future research, but the study was too small to determine effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Akita University Hospital

    Akita, Akita, 010-8543, Japan

  • Fukushima Medical University Hospital

    Fukushima, Fukushima, 960-1295, Japan

  • Kanazawa University Hospital

    Kanazawa, Ishikawa-ken, 920-8641, Japan

  • Kurume University Hospital

    Kurume-shi, Fukuoka, 830-0011, Japan

  • Kyushu University Hospital

    Fukuoka, Fukuoka, 812-8582, Japan

  • Yamagata University Hospital

    Yamagata, Yamagata, 990-9585, Japan

Conditions

Explore the condition pages connected to this study.

B PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA B PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA